Navigation Links
Deloitte Recap Honors Sanofi-aventis and Exelixis With the Allicense 2010 Breakthrough Alliance Award for Early-Stage Collaboration in Cancer
Date:8/31/2010

SAN FRANCISCO, Aug. 31 /PRNewswire/ -- Deloitte Recap recently presented the Allicense 2010 Breakthrough Alliance Award to pharmaceutical giant, Sanofi-aventis, and biotechnology firm, Exelixis, in recognition of their potential $1 billion alliance in which Exelixis gave Sanofi-aventis worldwide exclusive licenses for two early-stage cancer treatments and a stake in the development of PI3K inhibitor programs.  In exchange, Sanofi-aventis provided Exelixis an upfront payment of $140 million with an additional guaranteed $21 million over the next three years for research and development and could total up to $1 billion in milestone payments.

The annual award, presented at the Deloitte Recap Allicense conference, honors the efforts of business development licensing professionals.  Deloitte Recap analysts examined hundreds of biotech/big pharma deals signed in the previous year to identify the top five contenders for the deal of the year.  Business development licensing professionals throughout the industry voted to identify a winner.  

"Combining the research innovation of the biotech companies with the resources of global pharmaceutical corporations is essential to continued productivity in the life sciences industry," said Mark Edwards, managing director of Deloitte Recap LLC.

"Sanofi-aventis is extremely honored to have received the Allicense 2010 Deal of the Year Award for the Exelixis transaction," said Philippe Goupit, vice president of corporate licenses at Sanofi-aventis.  "This transaction perfectly reflects our new strategy to engage true collaborative partnerships with highly reputable innovative biotech companies such as Exelixis.  There is a lot to get out from such innovative types of collaboration for the ultimate benefit of patients."

Exelixis also was honored to win the Breakthrough Alliance Award in 2010 and 2009.  "We are very excited to receive the Allicense deal award for a second y
'/>"/>

SOURCE Deloitte
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Verathon Inc., Maker of BladderScan(R) and GlideScope(R), Ranks in Deloittes 2008 Washington State Technology Fast 50 for 5th Time in Past 7 Years
2. Althea Technologies Receives Fast Growth Honors: Deloitte Technology Fast 50 and San Diego Business Journal Fast 100 Awards for the Fifth Consecutive Year
3. AMDL, Inc. Named to Deloitte LLC Technology Fast 50
4. Sundia MediTech Ranked #16 in Deloitte Technology Fast 50 China
5. Sinovac Named to Deloitte Technology Fast 50 China
6. Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloittes 2008 Technology Fast 500
7. Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report
8. Sundia MediTech in Deloitte Technology Fast 500 Asia Pacific List
9. Deloitte Recap Launches New Series of Biopharmaceutical Business Intelligence Tools
10. Cadient Group Ranks as Deloitte Fast 50 Company for Greater Philadelphia Region for Second Consecutive Year
11. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... This is ... report provides a basic overview of the industry including definitions, classifications, applications and ... including development trends, competitive landscape analysis, and key regions development status. Development policies ...
(Date:7/27/2015)... --  Inocucor Technologies Inc ., the agriculture biotech ... has received a notice of allowance from the ... application to protect Inocucor consortia and unique microbial ... on farms and in greenhouses. This ... consortium and its fermentation byproducts, which are the ...
(Date:7/27/2015)... , July 27, 2015 According to ... Type (Home-brew Media, Pre-formulated Media), by Application (Biobanking, Regenerative Medicine, ... Europe , Asia-Pacific , ... The global biopreservation media market was valued at $247.7 million ... million by 2019, at a CAGR of 18.2% between 2014 ...
(Date:7/27/2015)... WESTBROOK, Maine , July 27, 2015 ... that more than 8,000 clinics have submitted over 100,000 ... SDMA, testing in just the first 10 days since ... Chronic kidney disease (CKD) is a leading cause of ... from the submitted specimens are consistent with generally accepted ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 2Inocucor Technologies Receives Groundbreaking U.S. Patent for Proprietary Biological Processes that Stimulate Plant Growth 3Global Biopreservation Media Market to be Worth $571.5 Million by 2019 2Global Biopreservation Media Market to be Worth $571.5 Million by 2019 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 2Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 3Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 4Over 100,000 Pets Tested with New IDEXX SDMA Kidney Function Test Since Product Launch on July 13 5
... RIVER, N.Y., June 20, 2011 ... provider of software and services for health and ... 4.2 electronic health record (EHR) software for behavioral ... ARRA Ambulatory Certification. (Logo: http://photos.prnewswire.com/prnh/20110620/NY22778LOGO) ...
... VICTORIA, Australia, June 20, 2011 Genetic Technologies Limited ... North American division, Phenogen Sciences Inc., has launched the ... risk.   Phenogen Sciences will target its ... US metro-markets.  The company has deployed its sales force ...
... ,Graphene, a one-atom-thick layer of graphitic carbon, has the ... But its unique properties, and the shrinking scale of ... produce on a large scale. In ... had overcome some of these difficulties and were able ...
Cached Biology Technology:CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 2CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 3CMHC/MIS Electronic Health Record Solution from Netsmart Technologies Attains Complete ARRA Certification 4Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 2Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 3Genetic Technologies Launches BREVAGen™ Breast Cancer Risk Test in US 4UCLA team reports scalable fabrication of self-aligned graphene transistors, circuits 2
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/8/2015)... July 8, 2015  Trovagene, Inc. (NASDAQ: ... today announced the launch of a study that ... Cancer Monitoring℠ (PCM) technology for predicting response to ... a combination of the novel immunotherapy agents Yervoy® ... PD-1 inhibitor. The 50-patient study will be led ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... a new study, Dartmouth researchers describe the structure of a ... Vibrio cholerae , the bacteria that causes cholera. Buried within ... that appears to inhibit ToxT, which prevents the bacteria from ... threatening, and, according to the World Health Organization, cholera remains ...
... In fact, toe running is far more efficient than landing ... distance endurance running, humans are some of the best-adapted animals ... why have we stuck with our inefficient heel first footfall ... marathon running? This paradox puzzled Nadja Schilling and Christoph Anders ...
... Scientists have pinpointed specific mutations that allow a common ... in the March issue of the Journal of General ... viruses and hosts could provide insight to how some viruses ... a better idea of how animal diseases are generated. ...
Cached Biology News:Dartmouth researchers describe how the cholera bacteria becomes infectious 2Human use heel first gait because it is efficient for walking 2The genetic secrets to jumping the species barrier 2
The F40 pump maintenance kit is used to service one F40 pump of a BioLogic DuoFlow workstation. It includes 2 piston seals, 4 check valves, seal removal tool, and 2 O-rings....
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES...
... antibody raised against a partial ... Immunogen: SLC22A3 (NP_068812, 90 ... recombinant protein with GST tag. ... NM_021977 ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Biology Products: